BRPI0311189B8 - composições farmacêuticas contendo polimorfo a de flibanserin, bem como seu uso - Google Patents

composições farmacêuticas contendo polimorfo a de flibanserin, bem como seu uso

Info

Publication number
BRPI0311189B8
BRPI0311189B8 BRPI0311189A BR0311189A BRPI0311189B8 BR PI0311189 B8 BRPI0311189 B8 BR PI0311189B8 BR PI0311189 A BRPI0311189 A BR PI0311189A BR 0311189 A BR0311189 A BR 0311189A BR PI0311189 B8 BRPI0311189 B8 BR PI0311189B8
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
compositions containing
well
flibanserin polymorph
containing flibanserin
Prior art date
Application number
BRPI0311189A
Other languages
English (en)
Portuguese (pt)
Other versions
BR0311189A (pt
BRPI0311189B1 (pt
Inventor
Bernhard Edmund Radtke Guido
Friedl Thomas
Original Assignee
Boehringer Ingelheim Pharma
Sprout Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma, Sprout Pharmaceuticals Inc filed Critical Boehringer Ingelheim Pharma
Publication of BR0311189A publication Critical patent/BR0311189A/pt
Publication of BRPI0311189B1 publication Critical patent/BRPI0311189B1/pt
Publication of BRPI0311189B8 publication Critical patent/BRPI0311189B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BRPI0311189A 2002-05-22 2003-05-19 composições farmacêuticas contendo polimorfo a de flibanserin, bem como seu uso BRPI0311189B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02011224.9 2002-05-22
EP02011224 2002-05-22
PCT/EP2003/005226 WO2003097058A1 (en) 2002-05-22 2003-05-19 New pharmaceutical compositions containing flibanserin polymorph a

Publications (3)

Publication Number Publication Date
BR0311189A BR0311189A (pt) 2005-02-22
BRPI0311189B1 BRPI0311189B1 (pt) 2019-04-09
BRPI0311189B8 true BRPI0311189B8 (pt) 2021-05-25

Family

ID=29433081

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0311189A BRPI0311189B8 (pt) 2002-05-22 2003-05-19 composições farmacêuticas contendo polimorfo a de flibanserin, bem como seu uso

Country Status (25)

Country Link
EP (1) EP1511489B1 (enExample)
JP (1) JP3919788B2 (enExample)
KR (1) KR101054237B1 (enExample)
CN (3) CN102240289A (enExample)
AT (1) ATE499939T1 (enExample)
BR (1) BRPI0311189B8 (enExample)
CA (1) CA2483597C (enExample)
CY (1) CY1111470T1 (enExample)
DE (1) DE60336225D1 (enExample)
DK (1) DK1511489T3 (enExample)
EA (1) EA007185B1 (enExample)
EC (1) ECSP045493A (enExample)
ES (1) ES2361994T3 (enExample)
HR (1) HRP20041092B1 (enExample)
IL (1) IL164440A0 (enExample)
ME (1) MEP55308A (enExample)
MX (1) MXPA04011487A (enExample)
NO (1) NO329414B1 (enExample)
NZ (1) NZ537253A (enExample)
PL (1) PL211062B1 (enExample)
RS (1) RS51718B (enExample)
SI (1) SI1511489T1 (enExample)
UA (1) UA80135C2 (enExample)
WO (1) WO2003097058A1 (enExample)
ZA (1) ZA200408151B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183410B2 (en) 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
CA2608713A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of sexual dysfunctions due to medical conditions
JP2008540673A (ja) * 2005-05-19 2008-11-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 薬剤誘発性性機能不全の治療方法
EP1912650B8 (en) 2005-08-03 2017-10-18 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
EP1945214A1 (en) 2005-10-29 2008-07-23 Boehringer Ingelheim International GmbH Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
JP2009541443A (ja) * 2006-06-30 2009-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 尿失禁及び関連疾患の治療のためのフリバンセリン
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
KR20090042967A (ko) 2006-08-14 2009-05-04 베링거 인겔하임 인터내셔날 게엠베하 플리반세린 제형 및 이의 제조방법
CN104721168A (zh) 2006-08-25 2015-06-24 贝林格尔·英格海姆国际有限公司 控制释放系统及其制造方法
WO2008074795A1 (en) 2006-12-20 2008-06-26 Boehringer Ingelheim International Gmbh Sulfated benzimidazolone derivatives having mixed serotonine receptor affinity
EP1955699A1 (en) * 2007-02-08 2008-08-13 Boehringer Ingelheim Pharma GmbH & Co. KG Use of flibanserin for the treatment of insomnia
CL2008002693A1 (es) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
EP2090297A1 (en) * 2008-02-13 2009-08-19 Boehringer Ingelheim International GmbH Formulations of flibanserin
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
US20120010216A1 (en) * 2010-07-06 2012-01-12 Brown Arthur M Pharmaceutical compositions containing vanoxerine
CN104926734B (zh) * 2015-07-07 2017-04-05 苏州立新制药有限公司 氟班色林的制备方法
WO2017128932A1 (zh) * 2016-01-31 2017-08-03 孟晓明 氟班色林的新晶型及其制备方法及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone
AU2002331361B2 (en) * 2001-08-02 2008-06-05 Sprout Pharmaceuticals, Inc. Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
DE10138273A1 (de) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Arzneimittel mit neuroprotektiver Wirkung

Also Published As

Publication number Publication date
CA2483597C (en) 2010-02-09
CN1655789A (zh) 2005-08-17
MEP55308A (en) 2011-05-10
PL211062B1 (pl) 2012-04-30
BR0311189A (pt) 2005-02-22
DK1511489T3 (da) 2011-05-02
CN101002780A (zh) 2007-07-25
ES2361994T3 (es) 2011-06-27
WO2003097058A1 (en) 2003-11-27
KR20040111668A (ko) 2004-12-31
MXPA04011487A (es) 2005-02-14
NZ537253A (en) 2007-09-28
UA80135C2 (en) 2007-08-27
CN102240289A (zh) 2011-11-16
HRP20041092B1 (hr) 2013-05-31
JP2005530787A (ja) 2005-10-13
RS98704A (sr) 2006-12-15
ZA200408151B (en) 2006-06-28
IL164440A0 (en) 2005-12-18
KR101054237B1 (ko) 2011-08-08
JP3919788B2 (ja) 2007-05-30
NO329414B1 (no) 2010-10-18
NO20044547L (no) 2004-12-17
HRP20041092A2 (en) 2005-06-30
SI1511489T1 (sl) 2011-06-30
EP1511489A1 (en) 2005-03-09
EA007185B1 (ru) 2006-08-25
CA2483597A1 (en) 2003-11-27
EP1511489B1 (en) 2011-03-02
DE60336225D1 (de) 2011-04-14
PL372457A1 (en) 2005-07-25
BRPI0311189B1 (pt) 2019-04-09
AU2003240672A1 (en) 2003-12-02
EA200401515A1 (ru) 2005-06-30
ECSP045493A (es) 2005-03-10
RS51718B (sr) 2011-10-31
CY1111470T1 (el) 2015-08-05
ATE499939T1 (de) 2011-03-15

Similar Documents

Publication Publication Date Title
BRPI0311189B8 (pt) composições farmacêuticas contendo polimorfo a de flibanserin, bem como seu uso
BRPI0311275A2 (pt) "composições de fenofibrato estáveis para administração oral, bem como uso das mesmas"
RS20120139A3 (en) 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments
BRPI0417717A (pt) composto, composição farmacêutica, e, uso de um composto
NO20063429L (no) Brusende oral opiat doseringsform
BRPI0409133B8 (pt) preparações farmacêuticas estavéis compreendendo metilnaltrexona
ITMI20031570A1 (it) Composizione per uso dietetico, farmaceutico o cosmetico
BR0306870A (pt) Composição farmacêutica oral, e, método para preparar a mesma
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
SE0301653D0 (sv) Novel compounds
MY140630A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
EA200500213A1 (ru) Диспергируемые таблетки для орального назначения
SE0301701D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0301699D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
ITRM20030363A0 (it) Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico diesse.
BRPI0408848B8 (pt) composições farmacêuticas de complexo de ciclodextrina-cladribina complexo, usos do referido complexo, bem como processos para a sua preparação
ECSP066860A (es) Formulaciones de matriz oral que comprenden licarbazepina
SE0300457D0 (sv) Novel compounds
TW200503785A (en) Dosage form containing (S)-pantoprazole as active ingredient
TW200503783A (en) Oral pharmaceutical preparation for proton pump antagonists
AR048672A1 (es) Tabletas de desintegracion que comprenden licarbazepina
MX2009008813A (es) Composicion farmaceutica que contiene floroglucinol y paracetamol.
PA8646301A1 (es) Inhibidores de la adenilato ciclasa soluble
UA87152C2 (ru) Твердая фармацевтическая композиция, содержащая миртазапин, и способ ее получения
ATE357220T1 (de) Pharmazeutische zusammensetzung mit modifizierter freisetzung

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: "PARA: INT. CL. A61K 31/496, 9/20

Ipc: A61K 31/496 (2011.01), A61K 9/20 (2011.01), A61P 2

Free format text: PARA: INT. CL. A61K 31/496, 9/20; A61P 25/16, 25/18, 25/20, 25/22, 25/24, 25/28

Ipc: A61K 31/496 (2011.01), A61K 9/20 (2011.01), A61P 2

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: SPROUT PHARMACEUTICALS, INC. (US)

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/04/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/04/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/05/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 20A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2724 DE 21-03-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.